REG - Irish Takeover Panel - Disclosure Table

Horizon TherapeuticsAnnouncement

06/10/2023 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231006:nRSF9960Oa&default-theme=true

RNS Number : 9960O  Irish Takeover Panel  06 October 2023

IRISH TAKEOVER PANEL
 
Disclosure Table
 

The following companies are deemed to be in an offer period for the purposes
of disclosure under the Rules of the Irish Takeover Panel:

_______________________________________________________________

Offeree:          Horizon Therapeutics plc

Offer period commenced:  29 November 2022

$0.0001 ordinary shares; ISIN: IE00BQPVQZ61; NSI: 228,928,661

Offeror:          Amgen Inc

Disclosure of dealings and positions in this offeror is not required

Offeror identified: 29 November 2022

Rule 2.6(a) deadline: N/A

 

Offeree:          Glantus Holdings plc

Offer period commenced:  05 July 2023

€0.001 ordinary shares; ISIN: IE00BNG2V304; NSI: 51,132,553

Offeror:          Accel-KKR Company LLC

Disclosure of dealings and positions in this offeror is not required

Offeror identified: 5 July 2023

Rule 2.6(a) deadline: N/A

 

 

Offeree:          MariaDB plc

Offer period commenced:  15 September 2023

$0.01 ordinary shares; ISIN: IE0008908NI4; NSI: 67,713,368

Offeror:          Runa Capital II(GP)

Disclosure of dealings and positions in this offeror is not required

Offeror identified: 15 September 2023

Rule 2.6(a) deadline: 17:00 on 27 October 2023

 

 

Irish Takeover
Panel                                   06
October 2023

Lower Ground Floor

76 Merrion Square

Dublin D02 X4T1

 

Telephone:    + 353-1-678 9020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEFZMGGLVNGFZG